J. Thaddeus Beck
About
J. Thaddeus Beck is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology.
According to data from OpenAlex, J. Thaddeus Beck has authored 74 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Oncology, 46 papers in Pulmonary and Respiratory Medicine and 23 papers in Molecular Biology. Recurrent topics in J. Thaddeus Beck's work include Advanced Breast Cancer Therapies (26 papers), Cancer Treatment and Pharmacology (15 papers) and Cancer Genomics and Diagnostics (12 papers). J. Thaddeus Beck is often cited by papers focused on Advanced Breast Cancer Therapies (26 papers), Cancer Treatment and Pharmacology (15 papers) and Cancer Genomics and Diagnostics (12 papers). J. Thaddeus Beck collaborates with scholars based in United States, Canada and Italy. J. Thaddeus Beck's co-authors include W G Harker, C. W. Seidler, Adam Brufsky, Edith A. Perez, John Hohneker, Elizabeth Tan-Chiu, Robert R. Carroll, Leo V. Lacerna, Stephanie Petrone and Keren Sturtz and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.
In The Last Decade
J. Thaddeus Beck
70 papers receiving 2.0k citations
Hit Papers
Peers
J. Thaddeus Beck
Günther Steger Austria
Edda Simoncini Italy
José Á. García-Sáenz Spain
H. Hausmaninger Austria
Lara Lipton Australia
Carla I. Falkson United States
Suhail M. Ali United States
V J Bardou France
A. Jo Chien United States
B. Massidda Italy
Citations per year, relative to J. Thaddeus Beck J. Thaddeus Beck (= 1×)
peers
Günther Steger
Countries citing papers authored by J. Thaddeus Beck
Since
Specialization
Citations
This map shows the geographic impact of J. Thaddeus Beck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Thaddeus Beck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Thaddeus Beck more than expected).
Fields of papers citing papers by J. Thaddeus Beck
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by J. Thaddeus Beck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Thaddeus Beck. The network helps show where J. Thaddeus Beck may publish in the future.
Co-authorship network of co-authors of J. Thaddeus Beck
This figure shows the co-authorship network connecting the top 25 collaborators of J. Thaddeus Beck. A scholar is included among the top collaborators of J. Thaddeus Beck based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Thaddeus Beck. J. Thaddeus Beck is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Beck, J. Thaddeus, Dale R. Shepard, Olivier Dumas, et al.. (2024). A phase 1, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of PF-07799544 (ARRY-134) as a single agent and in combination with PF-07799933 BRAF dimer inhibitor, in participants 16 years and older with advanced solid tumors.. Journal of Clinical Oncology. 42(16_suppl). TPS3180–TPS3180.
2.
Telli, Melinda L., Jennifer K. Litton, J. Thaddeus Beck, et al.. (2024). Neoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer: exploration of tumor BRCA mutational status. Breast Cancer. 31(5). 886–897.
3.
Rodón, Jordi, Daniel Shao-Weng Tan, Ignacio Garrido‐Laguna, et al.. (2023). Avelumab or talazoparib in combination with binimetinib in metastatic pancreatic ductal adenocarcinoma: dose-finding results from phase Ib of the JAVELIN PARP MEKi trial. ESMO Open. 8(4). 101584–101584.
4.
Tolaney, Sara M., Muralidhar Beeram, J. Thaddeus Beck, et al.. (2022). Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study. Frontiers in Oncology. 11. 810023–810023.
5.
Raghav, Kanwal, Takayuki Yoshino, Hiroya Taniguchi, et al.. (2021). P-45 An open-label, phase 2 study of patritumab deruxtecan in patients with previously treated advanced/metastatic colorectal cancer. Annals of Oncology. 32. S111–S111.
6.
Bardia, Aditya, Marina Parton, Sherko Kümmel, et al.. (2018). Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant Trial. Journal of Clinical Oncology. 36(31). 3126–3133.
7.
Yap, Timothy A., J. Thaddeus Beck, Ross Stewart, et al.. (2018). JAVELIN PARP medley: A phase Ib/II study of avelumab (anti–PD-L1) plus talazoparib in locally advanced or metastatic solid tumors. Annals of Oncology. 29. viii441–viii441.
8.
Rugo, Hope S., Lasika Seneviratne, J. Thaddeus Beck, et al.. (2017). Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial. The Lancet Oncology. 18(5). 654–662.
9.
Kieber‐Emmons, Thomas, Issam Makhoul, Angela Pennisi, et al.. (2017). Managing Expectations in the Transition to Proof of Concept Studies. Reviews on Recent Clinical Trials. 12(2). 111–123.
10.
Knox, Jennifer J., Carlos H. Barrios, T.M. Kim, et al.. (2017). Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC. Annals of Oncology. 28(6). 1339–1345.
11.
Hingorani, Sunil R., William Proctor Harris, J. Thaddeus Beck, et al.. (2016). Phase Ib Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer. Clinical Cancer Research. 22(12). 2848–2854.
12.
Voss, Martin H., Rupal S. Bhatt, Elizabeth R. Plimack, et al.. (2016). The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma. Clinical Cancer Research. 23(14). 3557–3565.
13.
Goss, Paul E., James N. Ingle, Kathleen I. Pritchard, et al.. (2016). Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. New England Journal of Medicine. 375(3). 209–219.
14.
Rodón, Jordi, Giuseppe Curigliano, Jean‐Pierre Delord, et al.. (2016). A phase Ib dose-finding study of alpelisib (ALP; BYL719) and paclitaxel (PTX) in advanced solid tumors (aST). Annals of Oncology. 27. vi119–vi119.
15.
Goss, Paul E., James N. Ingle, Kathleen I. Pritchard, et al.. (2016). A randomized trial (MA.17R) of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer.. Journal of Clinical Oncology. 34(18_suppl). LBA1–LBA1.
16.
Quoix, Élisabeth, György Losonczy, Frédéric Forget, et al.. (2014). TIME, a Phase 2b/3 Study Evaluating TG4010 in Combination With First-Line Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC): Phase 2b Results. International Journal of Radiation Oncology*Biology*Physics. 90(5). S35–S35.
17.
Feld, Ronald, Margaret M. Woo, Natasha B. Leighl, et al.. (2013). A clinical investigation of inhibitory effect of panobinostat on CYP2D6 substrate in patients with advanced cancer. Cancer Chemotherapy and Pharmacology. 72(4). 747–755.
18.
Brufsky, Adam, W G Harker, J. Thaddeus Beck, et al.. (2011). Final 5‐year results of Z‐FAST trial. Cancer. 118(5). 1192–1201.
19.
Awada, Ahmad, Luc Dirix, J. Thaddeus Beck, et al.. (2009). Safety and Efficacy of Neratinib (HKI-272) in Combination with Vinorelbine in ErbB2+ Metastatic Breast Cancer.. Cancer Research. 69(24_Supplement). 5095–5095.
20.
Beck, J. Thaddeus, Giuseppe Procopio, Elena Verzoni, et al.. (2008). Large open-label, non-comparative, clinical experience trial of the multi-targeted kinase inhibitor sorafenib in European patients with advanced RCC. Journal of Clinical Oncology. 26(15_suppl). 16021–16021.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Günther Steger Breakdown of academic impact, for papers by Edda Simoncini Breakdown of academic impact, for papers by José Á. García-Sáenz Breakdown of academic impact, for papers by H. Hausmaninger Breakdown of academic impact, for papers by Lara Lipton Breakdown of academic impact, for papers by Carla I. Falkson Breakdown of academic impact, for papers by Suhail M. Ali Breakdown of academic impact, for papers by V J Bardou Breakdown of academic impact, for papers by A. Jo Chien Breakdown of academic impact, for papers by B. Massidda